Repligen | RGEN - Interest Expense On Debt


Repligen reported $5.66M in Interest Expense on Debt for its fiscal quarter ending in June of 2026.





Interest Expense On Debt Change Date
Agilent USD 25M 0 Mar/2026
Align Technology USD 6.93M 9.11M Mar/2026
Bio Techne USD 3.6M 1.19M Jun/2026
BioMarin Pharmaceutical USD 63.29M 48.34M Jun/2026
Bristol-Myers Squibb USD 407M 4M Jun/2026
Bruker USD 17.8M 9.7M Jun/2026
Charles River Laboratories USD 30.34M 3.6M Jun/2026
Danaher USD 107M 44M Jun/2026
Dentsply International USD 22M 2M Jun/2026
General Electric Aerospace USD 496M 271M Dec/2025
Henry Schein USD 43M 4M Jun/2026
Illumina USD 24M 2M Mar/2026
IQVIA Holdings USD 197M 5M Jun/2026
Mettler Toledo International USD 17.25M 239K Jun/2026
Myriad Genetics USD 4.4M 600K Dec/2025
OraSure Technologies 1.67M 1.13M Dec/2025
Pacific Biosciences Of California USD 1.74M 1000 Dec/2025
Pfizer USD 667M 4M Jun/2026
Repligen USD 5.66M 85K Jun/2026
Revvity USD 22.99M 1.73M Jun/2026
Standard Biotools USD 5K 5K Dec/2025
Thermo Fisher Scientific USD 354M 11M Mar/2026
Waters USD 55M 13M Jun/2026
West Pharmaceutical Services USD 1.9M 1.7M Mar/2026